var data={"title":"Nonconvulsive status epilepticus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Nonconvulsive status epilepticus</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributors\" class=\"contributor contributor_credentials\">Nicolas Gaspard, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributors\" class=\"contributor contributor_credentials\">Jeffrey Jirsch, MD, MSc., FRCPC</a></dd><dd><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributors\" class=\"contributor contributor_credentials\">Lawrence J Hirsch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributors\" class=\"contributor contributor_credentials\">Paul Garcia, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 18, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H22466480\"><span class=\"h1\">INTRODUCTION AND DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonconvulsive status epilepticus (NCSE) was originally described in patients with chronic epilepsy, but it is now recognized with increased frequency in other patient populations, especially the critically ill.</p><p>The International League Against Epilepsy (ILAE) defines status epilepticus as a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/1\" class=\"abstract_t\">1</a>]. The temporal threshold that defines an abnormally prolonged seizure depends on the type of seizure. For convulsive status epilepticus, this duration is five minutes. For NCSE, defined as status epilepticus without prominent motor symptoms, the threshold is 10 minutes.</p><p>Not included in these new definitions, but still widely used by clinicians, is the situation in which brief intermittent seizure activity without convulsions occurs without full recovery of consciousness between attacks [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In patients with baseline coma or encephalopathy, NCSE typically includes patients with more than 30 total minutes of ictal electroencephalogram (EEG) activity in any given hour of recording (ie, &gt;50 percent of the record).</p><p>The diagnosis and treatment of NCSE are not straightforward and depend on many variables, including the clinical setting and etiology, EEG findings, and the clinical status of the patient. In addition, it is not always clear to what extent the electrographic activity contributes to clinical impairment or ongoing neuronal injury.</p><p>This topic reviews NCSE; convulsive status epilepticus is reviewed separately. (See <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Treatment and prognosis&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-complications-of-status-epilepticus-in-children\" class=\"medical medical_review\">&quot;Clinical features and complications of status epilepticus in children&quot;</a> and <a href=\"topic.htm?path=management-of-convulsive-status-epilepticus-in-children\" class=\"medical medical_review\">&quot;Management of convulsive status epilepticus in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22466573\"><span class=\"h1\">ELECTROCLINICAL CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the International League Against Epilepsy (ILAE) classification, NCSE is subdivided according to the level of consciousness and clinical and electroencephalogram (EEG) features [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/1\" class=\"abstract_t\">1</a>] (see <a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults#H2\" class=\"medical medical_review\">&quot;Overview of the management of epilepsy in adults&quot;, section on 'Classification'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NCSE without coma</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Generalized NCSE </p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Typical absence status epilepticus (ASE)</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Atypical ASE</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Myoclonic ASE</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Focal NCSE</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>With impairment of consciousness</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Without impairment of consciousness</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Aphasic status epilepticus</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Unknown whether focal or generalized NCSE</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Autonomic status epilepticus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NCSE with coma</p><p/><p>In addition, there are so-called &quot;boundary conditions&quot; that show evidence of ongoing electrographic epileptiform activity but lack clinical symptomatology that would conventionally be considered epileptic [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H28783851\"><span class=\"h2\">Typical absence status epilepticus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Typical ASE is a form of primary generalized NCSE that is almost always seen in patients with known genetic generalized epilepsy (previously known as idiopathic generalized epilepsy). Typical ASE has a characteristic EEG pattern of bilaterally synchronous spike-and-wave discharges occurring at a rate of 2.5 to 5 Hz (most commonly 3 Hz) (<a href=\"image.htm?imageKey=NEURO%2F88644\" class=\"graphic graphic_waveform graphicRef88644 \">waveform 1</a>).</p><p>ASE is uncommon but can occur in those patients with epilepsy syndromes in which typical absence seizures occur (ie, childhood absence, juvenile absence, or juvenile myoclonic epilepsy) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/4\" class=\"abstract_t\">4</a>]. In some cases, ASE may be precipitated by the use of an inappropriate antiseizure drug in a patient with genetic generalized epilepsy (most commonly <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, but also <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a> and <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/5\" class=\"abstract_t\">5</a>]. There are also rare cases of de novo ASE in adults. In older adult patients, this is often linked to withdrawal of benzodiazepines [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H28783858\"><span class=\"h2\">Atypical absence status epilepticus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atypical ASE is a form of generalized NCSE that has a slower spike-and-wave discharge pattern than typical absence status, approximately 1 to 2.5 Hz. This typically occurs in infants and children with epileptic encephalopathies, including Lennox-Gastaut syndrome. (See <a href=\"topic.htm?path=epilepsy-syndromes-in-children#H8\" class=\"medical medical_review\">&quot;Epilepsy syndromes in children&quot;, section on 'Lennox-Gastaut syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H1042785500\"><span class=\"h2\">Myoclonic absence status epilepticus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Myoclonic ASE is very rare. It occurs most often in genetic generalized epilepsy. Seizures are just like absence (with sudden onset of staring and impaired consciousness and generalized spike-wave EEG), but with myoclonic jerks time-locked to each spike-wave discharge. The myoclonus is usually fairly subtle, involving the eyelid or perioral musculature, but it can also be evident in axial or limb muscles.</p><p class=\"headingAnchor\" id=\"H15026272\"><span class=\"h2\">Focal status epilepticus without impairment of consciousness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal status epilepticus without impairment of consciousness (often still referred to as simple partial status epilepticus) is relatively uncommon and generally arises in patients with established focal epilepsy. Such patients have positive or negative symptomatology with preserved awareness with or without focal ictal activity on EEG; approximately half will not have a clear scalp EEG correlate.</p><p>Symptoms (eg, sensory, autonomic, cognitive) depend largely on the cerebral localization of the discharges. When subjective sensory or experiential phenomena are involved, this form of NCSE is known as &quot;aura continua&quot; [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/7\" class=\"abstract_t\">7</a>]. When focal motor activity is involved, it is referred to as epilepsia partialis continua and is classified as convulsive status epilepticus [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis#H2161854197\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis&quot;, section on 'Focal motor status epilepticus'</a>.)</p><p>Sudden-onset aphasia, usually mixed, can be the only manifestation of a language-dominant hemispheric NCSE, a condition known as aphasic status epilepticus.</p><p class=\"headingAnchor\" id=\"H28783865\"><span class=\"h2\">Focal status epilepticus with impairment of consciousness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prolonged focal seizures with impairment of consciousness or awareness in patients with chronic focal epilepsy are a form of NCSE, sometimes referred to as complex partial status epilepticus. Seizures most commonly originate from the temporal or frontal lobe.</p><p>EEG typically reveals focal discharges localized to the temporal or frontal lobe or generalized discharges indistinguishable from generalized-onset NCSE. Less commonly, there are no detectable EEG findings if the ictal activity is confined to deep structures [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/9\" class=\"abstract_t\">9</a>]. This type of status epilepticus is most common in adult patients, usually with a history of focal epilepsy, who are being evaluated for impaired consciousness or prolonged postictal confusion [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H542486148\"><span class=\"h2\">Nonconvulsive status epilepticus in coma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A substantial number of critically ill comatose children and adults in intensive care units (ICUs) who are monitored with EEG are found to have nonconvulsive seizures <span class=\"nowrap\">and/or</span> NCSE. Approximately 8 to 20 percent of comatose patients who have not had any clinical seizure activity will have EEG findings consistent with NCSE at the time of monitoring [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11-28\" class=\"abstract_t\">11-28</a>]. Risk factors for NCSE in the critically ill include severe alteration of consciousness (ie, coma), clinical seizures prior to monitoring, younger age (especially children), history of epilepsy or remote brain injury, recent neurosurgical procedure, acute brain injury, intracranial tumor, and sepsis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11-14,16,21,25,26,28-31\" class=\"abstract_t\">11-14,16,21,25,26,28-31</a>].</p><p class=\"headingAnchor\" id=\"H936096898\"><span class=\"h2\">Aftermath of convulsive status epilepticus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients treated for generalized convulsive status epilepticus are noted to have continuous ictal EEG activity after cessation of movements [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32-34\" class=\"abstract_t\">32-34</a>]. In one prospective study, NCSE was present in 14 percent of 164 patients monitored after treatment for convulsive status epilepticus; an additional 34 percent had intermittent ictal discharges that did not meet criteria for status [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32\" class=\"abstract_t\">32</a>].</p><p>In some cases, NCSE can occur after a single brief convulsive seizure, taking the form of a prolonged confusional state that is sometimes mistakenly thought to be postictal. Some use the term &quot;subtle status epilepticus&quot; for this specific scenario of periodic discharges or NCSE after convulsive status epilepticus, but this term is used less specifically in other instances. We prefer the term &quot;status epilepticus terminans&quot; when there are periodic discharges after convulsive seizures or convulsive status epilepticus, using the term &quot;subtle status epilepticus&quot; more broadly, as the name implies, for any form of status epilepticus with subtle or no clinical manifestations [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H28783642\"><span class=\"h1\">BOUNDARY CONDITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the above subtypes, NCSE also takes on distinct forms in early childhood, in the aftermath of generalized convulsive status epilepticus, and in the critically ill <span class=\"nowrap\">and/or</span> comatose patient.</p><p class=\"headingAnchor\" id=\"H4073668\"><span class=\"h2\">Neonatal and infantile epileptic encephalopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are a number of severe epileptic syndromes occurring primarily in the neonatal and infantile periods that take the form of continuous or near-continuous episodes of NCSE. These include some cases of West syndrome, Ohtahara syndrome, Dravet syndrome, and Lennox-Gastaut syndrome [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/3\" class=\"abstract_t\">3</a>]. These conditions are discussed separately. (See <a href=\"topic.htm?path=neonatal-epilepsy-syndromes#H13\" class=\"medical medical_review\">&quot;Neonatal epilepsy syndromes&quot;, section on 'Severe syndromes'</a> and <a href=\"topic.htm?path=epilepsy-syndromes-in-children#H8\" class=\"medical medical_review\">&quot;Epilepsy syndromes in children&quot;, section on 'Lennox-Gastaut syndrome'</a> and <a href=\"topic.htm?path=dravet-syndrome-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Dravet syndrome: Genetics, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H784277\"><span class=\"h2\">Electrical status epilepticus of sleep</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Electrical status epilepticus of sleep (ESES) is a rare form of NCSE characterized by the presence of 1 to 3 Hz spike-wave discharges occupying over 80 percent or more of the electroencephalogram (EEG) during non-rapid eye movement (non-REM) sleep. Many children with ESES exhibit symptoms of Landau-Kleffner syndrome, a rare syndrome characterized by progressive loss of language beginning at approximately three to six years of age. ESES is also the cardinal EEG finding in the syndrome of epileptic encephalopathy with continuous spikes and waves during sleep (CSWS). ESES has also been observed in association with other childhood electroclinical syndromes such as Lennox-Gastaut syndrome and benign epilepsy with centrotemporal spikes. These conditions are discussed separately. (See <a href=\"topic.htm?path=epilepsy-syndromes-in-children#H10\" class=\"medical medical_review\">&quot;Epilepsy syndromes in children&quot;, section on 'Syndromes with electrical status epilepticus during sleep'</a> and <a href=\"topic.htm?path=epilepsy-syndromes-in-children#H8\" class=\"medical medical_review\">&quot;Epilepsy syndromes in children&quot;, section on 'Lennox-Gastaut syndrome'</a> and <a href=\"topic.htm?path=benign-focal-epilepsies-of-childhood#H2\" class=\"medical medical_review\">&quot;Benign focal epilepsies of childhood&quot;, section on 'Benign epilepsy with centrotemporal spikes'</a>.)</p><p class=\"headingAnchor\" id=\"H795799703\"><span class=\"h2\">Coma or acute confusional states with epileptiform EEG patterns</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several clinical situations in which there is evidence of ongoing focal or generalized epileptiform activity by EEG, but in which the relationship of the EEG findings to the clinical scenario is not fully understood or agreed upon. In some cases, the controversy arises because of a lack of agreement as to whether the EEG changes are causative of the clinical condition or symptomatic of it. Such conditions include some cases of coma due to acute brain injury, some cases of epileptic behavioral disturbance or psychosis, and some cases of drug-induced or metabolic confusional states, often with myoclonic jerks, with evidence of epileptiform changes on EEG [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H784352\" class=\"local\">'Uncertain EEG patterns in critical illness'</a> below.)</p><p class=\"headingAnchor\" id=\"H28783649\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The underlying causes of NCSE are varied and differ according to the patient population being studied (eg, ambulatory versus critically ill). Approximately one-half to two-thirds of patients will have a prior history of seizures or epilepsy.</p><p>Typical and atypical absence status epilepticus (ASE) occurs primarily in children with generalized electroclinical syndromes in which absence seizures occur, or in infants and children with epileptic encephalopathies, as discussed above. (See <a href=\"#H28783851\" class=\"local\">'Typical absence status epilepticus'</a> above and <a href=\"#H28783858\" class=\"local\">'Atypical absence status epilepticus'</a> above.)</p><p>NCSE can be the presenting symptom of infectious or autoimmune encephalitis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/36-41\" class=\"abstract_t\">36-41</a>]. Conditions associated with the presence of a supernumerary ring chromosome (most frequently ring chromosome 20) can present with episodes of focal status epilepticus of frontal origin. These episodes are often subtle, manifesting only as mental slowing, and can last for hours or even days [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/42\" class=\"abstract_t\">42</a>].</p><p>The causes of NCSE in patients with known focal seizures are the same as the underlying causes of focal epilepsy, such as mesial temporal sclerosis, structural-metabolic causes (eg, malformations of cortical development, tumors, head trauma, stroke, vascular malformations), and various genetic focal epilepsies. Common precipitants include alcohol or antiseizure drug withdrawal, infections, sleep deprivation, and toxic or metabolic disturbances. (See <a href=\"topic.htm?path=localization-related-focal-epilepsy-causes-and-clinical-features#H2\" class=\"medical medical_review\">&quot;Localization-related (focal) epilepsy: Causes and clinical features&quot;, section on 'Etiologies'</a>.)</p><p>The underlying etiologies for NCSE in the aftermath of convulsive status epilepticus are similar to the causes of convulsive seizure in these patients. These include antiseizure drug nonadherence or discontinuation, other drug withdrawal syndromes, acute structural brain injury or infection, remote structural brain injury, metabolic derangements, and chronic epilepsy. (See <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis&quot;, section on 'Etiology'</a>.)</p><p>In critically ill patients found to have NCSE, common underlying diagnoses include subarachnoid hemorrhage, epilepsy, central nervous system infection, brain tumor, ischemic or hemorrhagic stroke, traumatic brain injury, <span class=\"nowrap\">hypoxia/anoxia,</span> and toxic-metabolic disturbance, including sepsis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11,12,14,15,21,26\" class=\"abstract_t\">11,12,14,15,21,26</a>].</p><p>Drug-induced NCSE is an important consideration in critically ill patients as well as cancer patients being treated with multiagent chemotherapy. NCSE due to beta-lactam antibiotics, particularly <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>, has been well described, most often in association with renal dysfunction [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/43-47\" class=\"abstract_t\">43-47</a>]. Other drugs that have been associated with NCSE include fluoroquinolones [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/48\" class=\"abstract_t\">48</a>], <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/49\" class=\"abstract_t\">49</a>], L-asparaginase [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/50\" class=\"abstract_t\">50</a>], <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/51\" class=\"abstract_t\">51</a>], and <a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">busulfan</a>. In some cases, NCSE is a presentation of drug-induced reversible posterior leukoencephalopathy syndrome (RPLS) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/52\" class=\"abstract_t\">52</a>]; among the more common culprits are <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, and agents that target angiogenesis (eg, <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>). (See <a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects#H13\" class=\"medical medical_review\">&quot;Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects&quot;, section on 'Neurologic reactions'</a> and <a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy\" class=\"medical medical_review\">&quot;Overview of neurologic complications of non-platinum cancer chemotherapy&quot;</a> and <a href=\"topic.htm?path=reversible-posterior-leukoencephalopathy-syndrome#H9\" class=\"medical medical_review\">&quot;Reversible posterior leukoencephalopathy syndrome&quot;, section on 'Associated conditions'</a>.)</p><p>New-onset refractory status epilepticus (NORSE) refers to cases of refractory status epilepticus (RSE) for which no etiology is identified within the first 48 hours. NORSE makes up less than 10 percent of patients presenting with status epilepticus but a higher proportion of patents with refractory NCSE [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/53-55\" class=\"abstract_t\">53-55</a>]. Up to 40 percent of patients are found to have an autoimmune or paraneoplastic encephalitis, but the etiology remains unknown in half of patients [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H4594405\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Impairment of consciousness ranging from mild confusion to coma is usually present in NCSE; focal status epilepticus without impairment in consciousness is less common.</p><p>Other clinical features of NCSE can vary widely and are often divided into two general categories: negative symptoms, which are impairments such as aphasia, mutism, amnesia and catatonia, and positive phenomenology, such as rhythmic twitching of one or more muscle groups, tonic eye deviation, hippus, or nystagmoid eye jerking (<a href=\"image.htm?imageKey=NEURO%2F88652\" class=\"graphic graphic_table graphicRef88652 \">table 1</a>). Positive symptoms are often subtle and can be overlooked. Some patients will have no manifestations of ongoing seizures other than coma, even when scrutinized by experienced clinicians. In fact, approximately three-quarters of critically ill patients with nonconvulsive seizures or NCSE will have no discernible clinical correlate and require electroencephalography (EEG) monitoring for diagnosis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/56,57\" class=\"abstract_t\">56,57</a>].</p><p>No single clinical symptom has been shown to be specific for a diagnosis of NCSE in patients with an acute change in mental status. In general, NCSE is more common with severe depression in consciousness (coma) than with milder alterations. Additional factors that increase the likelihood of nonconvulsive seizures or NCSE in a patient with altered mental state include ocular movement abnormalities (sustained eye deviation, nystagmus); remote risk factors for seizure, including a history of epilepsy; convulsive seizure during the current illness; and age less than one year [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/10,11,22,58\" class=\"abstract_t\">10,11,22,58</a>]. Automatisms such as lip smacking and subtle motor twitches in the face or extremities can be manifestations of NCSE but have low specificity (44 percent in one study); ocular movement abnormalities were a more specific finding (86 percent) in this study [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H22466611\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of NCSE requires an electroencephalogram (EEG), since clinical signs and symptoms are pleomorphic and nonspecific [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/59,60\" class=\"abstract_t\">59,60</a>]. In some cases an intravenous (IV) antiseizure drug trial is also required to help determine the significance of uncertain EEG patterns.</p><p class=\"headingAnchor\" id=\"H76178\"><span class=\"h2\">Patient selection for EEG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NCSE is much more common than previously recognized, particularly in intensive care unit (ICU) patients, and the diagnosis requires a high index of suspicion. As a general rule, any fluctuating or unexplained alteration in behavior or mental status warrants an EEG and consideration of NCSE, as does any acute supratentorial brain injury with altered level of consciousness.</p><p>EEG should also be considered routinely in certain clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aftermath of generalized convulsive status &ndash; Patients who present with generalized convulsive status epilepticus are typically expected to awaken gradually after the motor features of seizures disappear. If the level of consciousness is not improving by 10 minutes after cessation of movements, or the mental status remains abnormal 30 to 60 minutes after the convulsions cease, NCSE must be considered and urgent EEG is advised. NCSE can also occur after a single brief convulsion [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/61\" class=\"abstract_t\">61</a>].</p><p/><p class=\"bulletIndent1\">In one study, 14 percent of patients treated (seemingly) successfully for convulsive status epilepticus were in NCSE when EEG was begun; of the patients who underwent continuous EEG monitoring after convulsive status epilepticus was controlled, 48 percent had nonconvulsive seizures on monitoring [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32\" class=\"abstract_t\">32</a>]. Furthermore, once treatment for status epilepticus has begun, especially with continuous infusions, the vast majority (approximately 90 percent) of breakthrough seizures will be subclinical, with no clinical accompaniment aside from depressed mental status.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Critically ill patients who are obtunded or comatose &ndash; The diagnosis of NCSE in critically ill patients with obtundation or coma can be challenging, since manifestations are often absent or may consist only of subtle myoclonic limb, facial, or ocular movements, and because the underlying medical or neurologic condition might be deemed sufficient to explain the impaired consciousness. In fact, approximately 75 percent of seizures recorded in critically ill patients are unrecognized at the bedside and can only be diagnosed with EEG [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11,14,57\" class=\"abstract_t\">11,14,57</a>].</p><p/><p>Guidelines published by the Neurocritical Care Society on the evaluation and management of status epilepticus emphasize these indications and also recommend that continuous EEG be performed in the presence of any of the following: recent clinical seizure (of any duration) without return to baseline, postanoxic coma, intracranial hemorrhage, epileptiform activity <span class=\"nowrap\">and/or</span> periodic discharges in the first 30 minutes of EEG recording, and when nonconvulsive seizures are suspected in any patient with altered mental status [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H2970645\"><span class=\"h2\">Electroencephalography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The criteria for diagnosing NCSE in adults have largely focused on EEG patterns, combined with an acute IV antiseizure drug trial for patients in whom the diagnosis is in doubt. However, the ultimate interpretation of ictal versus nonictal epileptiform activity often remains unclear, even with expert EEG interpretation and proper antiseizure drug trials, particularly in critically ill patients.</p><p class=\"headingAnchor\" id=\"H664295002\"><span class=\"h3\">EEG patterns of definite NCSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EEG during NCSE is characterized by frequent seizures or continuous ictal activity corresponding to any of the following patterns [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/59,62-65\" class=\"abstract_t\">59,62-65</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients without known epileptic encephalopathy:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Focal or generalized spikes, sharp waves, or sharp-and-slow complexes at frequencies &gt;2.5 Hz</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Focal or generalized spikes, sharp waves, or sharp-and-slow complexes at frequencies &le;2.5 Hz or rhythmic activity &gt;0.5 Hz and one of the following:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Electrographic AND clinical improvement after an IV trial of an antiseizure drug (<a href=\"image.htm?imageKey=NEURO%2F88654\" class=\"graphic graphic_table graphicRef88654 \">table 2</a>)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Subtle clinical ictal phenomena during the EEG pattern</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Typical spatiotemporal evolution, including incrementing onset (increase in voltage and change in frequency), or evolution in pattern (change in frequency &gt;1 Hz or change in location), or decrementing termination (voltage or frequency)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with chronic epilepsy and an epileptic <span class=\"nowrap\">encephalopathy/syndrome:</span></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Frequent or continuous generalized spike-wave discharges, which show significant changes in intensity or frequency (usually a faster frequency) when compared with baseline EEG</p><p/><p>&quot;Frequent or continuous&quot; is somewhat arbitrary but is generally considered to mean more than 30 total minutes of ictal EEG activity in any given hour of recording (ie, &gt;50 percent of the record). To qualify for a diagnosis of NCSE, the whole EEG recording should be abnormal, and the EEG criteria should be met during at least 10 consecutive seconds. One study found that this threshold had the best diagnostic accuracy (93 percent) for NCSE, as retrospectively ascertained by a consensus of clinicians based on all the available clinical information [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/66\" class=\"abstract_t\">66</a>].</p><p>It is important to recognize that prolonged electrographic seizure activity can take several forms, some of which clearly denote NCSE and some of which are more difficult to interpret, probably denoting NCSE only in some cases [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/63\" class=\"abstract_t\">63</a>]. (See <a href=\"#H784352\" class=\"local\">'Uncertain EEG patterns in critical illness'</a> below.)</p><p class=\"headingAnchor\" id=\"H784352\"><span class=\"h3\">Uncertain EEG patterns in critical illness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In critically ill patients and in the aftermath of convulsive status epilepticus, common EEG findings include a range of periodic or rhythmic discharges (PDs) that do not meet formal seizure criteria. The American Clinical Neurophysiology Society (ACNS) has published a guideline with standardized nomenclature for these patterns [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/67\" class=\"abstract_t\">67</a>]. The nomenclature and an abbreviated &quot;pocket&quot; version are available on the <a href=\"http://www.acns.org/practice/guidelines&amp;token=ppy6PCRiE9HJgc+l6sW1ncilzn8LrT7IRpEiUHh4FNPnND/egVgd6dCX9fKi44S4&amp;TOPIC_ID=14103\" target=\"_blank\" class=\"external\">ACNS website</a>.</p><p>PDs are repetitive stereotyped discharges that occur at a nearly regular interval and with a quantifiable interdischarge interval. PDs may be generalized (GPDs as per the ACNS official nomenclature; also known as GPEDs) (<a href=\"image.htm?imageKey=NEPH%2F94773\" class=\"graphic graphic_waveform graphicRef94773 \">waveform 2</a>), lateralized (LPDs, also known as PLEDs) (<a href=\"image.htm?imageKey=NEURO%2F94774\" class=\"graphic graphic_waveform graphicRef94774 \">waveform 3</a>), bilateral but independent (BIPDs, also known as BIPLEDs) (<a href=\"image.htm?imageKey=NEURO%2F94775\" class=\"graphic graphic_waveform graphicRef94775 \">waveform 4</a>), or multifocal (MfPDs). (See <a href=\"topic.htm?path=electroencephalography-eeg-in-the-diagnosis-of-seizures-and-epilepsy#H6\" class=\"medical medical_review\">&quot;Electroencephalography (EEG) in the diagnosis of seizures and epilepsy&quot;, section on 'Lateralized periodic discharges'</a>.)</p><p>In the setting of status epilepticus, PDs lie on an <span class=\"nowrap\">ictal/interictal</span> continuum. They do not meet formal seizure criteria, and their exact nature and significance are poorly understood. Although certain features correlate with NCSE in grouped data (eg, longer GPD duration, higher GPD amplitude, and higher inter-GPD amplitude), the presence of GPDs on an EEG does not help to determine etiology, treatment, or prognosis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/68\" class=\"abstract_t\">68</a>]. Whether or not patients benefit from treatment of these EEG findings (including intermittent, brief nonconvulsive seizures) is currently unknown. (See <a href=\"#H22466618\" class=\"local\">'Treatment'</a> below.)</p><p>GPDs are often observed in critically ill patients (<a href=\"image.htm?imageKey=NEPH%2F94773\" class=\"graphic graphic_waveform graphicRef94773 \">waveform 2</a>) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/69\" class=\"abstract_t\">69</a>]. In a single-center review of over 3000 continuous EEG recordings, GPDs were present in 4.5 percent of patients and correlated with nonconvulsive seizures and NCSE [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/70\" class=\"abstract_t\">70</a>]. Specifically, 27 percent of patients with GPDs had evidence of nonconvulsive seizures elsewhere in the same recording, compared with 8 percent of critically ill matched controls without GPDs. Although GPDs have also been described as a postictal pattern after convulsive status epilepticus, they were not associated with convulsive seizures or convulsive status in this study.</p><p>GPDs at a frequency of greater than 1 Hz sometimes signify NCSE. However, a similar pattern can be seen in toxic-metabolic encephalopathy (eg, &quot;triphasic waves&quot;), Creutzfeldt-Jakob disease, Hashimoto encephalopathy, and from medications such as <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, <a href=\"topic.htm?path=baclofen-drug-information\" class=\"drug drug_general\">baclofen</a>, <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>, and <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">ifosfamide</a>.</p><p>Other epileptiform discharges seen in critical illness, including LPDs, lateralized rhythmic delta activity (LRDA), and BIPDs, have been associated with NCSE elsewhere in the recording but are usually not indicative of seizures in isolation [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11,12,14\" class=\"abstract_t\">11,12,14</a>]. For LRDA and GPDs, the risk of seizure elsewhere in the recording correlates with higher frequencies (&gt;1.5 Hz) and higher burden of discharges [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/71\" class=\"abstract_t\">71</a>]. In some cases, these patterns are more likely to be ictal:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPDs associated with low-voltage rhythmic discharges &gt;4 Hz, referred to as LPDs plus (LPDs+) or PLEDs plus, are often associated with seizures (<a href=\"image.htm?imageKey=NEURO%2F94776\" class=\"graphic graphic_waveform graphicRef94776 \">waveform 5</a>) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/69,72\" class=\"abstract_t\">69,72</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When LPDs or rhythmic delta are superimposed and fluctuating in frequency, or when periodic discharges reach frequencies &ge;1.5 Hz, these patterns are suspicious for seizures and considered to be on the ictal-interictal continuum [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/73-75\" class=\"abstract_t\">73-75</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPDs and BIPDs associated with positive signs and symptoms (eg, subtle motor activity, hallucinations, confusion) or negative signs and symptoms (eg, aphasia, cortical blindness) are by definition ictal [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/76,77\" class=\"abstract_t\">76,77</a>].</p><p/><p>Stimulus-induced rhythmic periodic, or ictal discharges (SIRPIDs), such as those provoked by suctioning, examination, or loud noise, are a common EEG feature in critically ill patients (<a href=\"image.htm?imageKey=NEURO%2F94777\" class=\"graphic graphic_waveform graphicRef94777 \">waveform 6</a>). SIRPIDs usually last for a few minutes but can be shorter or longer depending upon the amount of ongoing stimulation. Some SIRPIDs have a rhythmic, evolving ictal pattern and others do not [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/78\" class=\"abstract_t\">78</a>]. SIRPIDs are associated with a greater chance for finding electrographic seizures elsewhere in the recording but are not independently associated with increased mortality [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/79\" class=\"abstract_t\">79</a>]. The fact that they are stimulus-induced does not alter the association with seizures in either direction; the risk is the same whether the pattern is stimulus-induced or spontaneous [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/71\" class=\"abstract_t\">71</a>]. </p><p class=\"headingAnchor\" id=\"H784360\"><span class=\"h3\">Duration of monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While most critically ill patients with nonconvulsive seizures have their first seizure within 24 hours of the start of a recording, a substantial minority require 48 hours or longer to detect clinically relevant nonconvulsive seizures [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11\" class=\"abstract_t\">11</a>]. Only half of patients will have their first seizure within the first hour of recording.</p><p>The likelihood of a seizure occurring depends heavily on two clinical risk factors (comatose state, history of acute or remote seizures) and on the presence of a high-risk EEG pattern (eg, LPDs, LRDA, or other epileptiform abnormalities) during the initial recording [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/71,80\" class=\"abstract_t\">71,80</a>]. In a study that included 665 consecutive continuous EEGs in critically ill patients, the risk of developing a seizure on monitoring was as high as 64 percent at 72 hours in patients with coma and a history of seizure and as low as 9 percent in those with no clinical or EEG risk factors [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/80\" class=\"abstract_t\">80</a>]. Although there is some variability across studies, the projected risk of seizure when there are no high-risk EEG features declines rapidly over time and is &lt;5 percent at 24 hours, except in patients who are comatose and have had prior seizures [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/80-82\" class=\"abstract_t\">80-82</a>].</p><p>Monitoring duration should therefore be individualized [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/83,84\" class=\"abstract_t\">83,84</a>]. For patients without high-risk clinical features, 24 hours of continuous EEG recording is a reasonable screen for nonconvulsive seizures, provided no epileptiform discharges emerge. More prolonged recording (up to 72 hours) is recommended in patients with epileptiform discharges, especially if discharges are periodic, and in patients who are comatose and have a history of prior seizures. The goal of monitoring is to facilitate early identification and treatment of NCSE; the clinical utility of detecting isolated, infrequent subclinical seizures has not been well established.</p><p class=\"headingAnchor\" id=\"H837656464\"><span class=\"h3\">EEG electrode array for monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A full EEG array is based upon the international 10-20 system and remains the technical standard for the EEG diagnosis and monitoring of nonconvulsive seizures. The application and maintenance of EEG leads can be time consuming in the hospital, however, and efforts to improve efficiency have led to reduced 7-lead or 8-lead &quot;subhairline&quot; arrays [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/85\" class=\"abstract_t\">85</a>] and other algorithmic analyses of spectral subparameters using as few as two electrodes [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/86\" class=\"abstract_t\">86</a>].</p><p>The sensitivity for detection of ictal and interictal epileptiform abnormalities using a reduced EEG electrode array is significantly lower than the standard full EEG array, however (39 versus 68 percent) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/85\" class=\"abstract_t\">85</a>]. Specificity is also lost, as artifacts or physiologic nonictal rhythmic patterns are more likely to be misinterpreted as seizures.</p><p>We therefore recommend using the full array of electrodes based upon the international 10-20 system for detection and management of nonconvulsive seizures in routine clinical care, limiting more simplified EEG techniques to cases where full EEG is not available; when it becomes available, the full array should be used [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/84\" class=\"abstract_t\">84</a>].</p><p class=\"headingAnchor\" id=\"H627169\"><span class=\"h2\">Acute IV antiseizure drug trial</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One strategy for distinguishing ictal from nonictal EEG patterns, and for addressing equivocal patterns on the ictal-interictal continuum [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/73-75\" class=\"abstract_t\">73-75</a>], is to determine if the pattern is abolished by a trial of an IV antiseizure drug and the patient improves clinically [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/69\" class=\"abstract_t\">69</a>]. In particular, we suggest an IV antiseizure drug trial for cases in which the EEG shows repetitive generalized or focal spikes, sharp waves, or spike-and-wave complexes at &lt;3 Hz that do not have a clear evolution in frequency, morphology, or location (<a href=\"image.htm?imageKey=NEURO%2F88654\" class=\"graphic graphic_table graphicRef88654 \">table 2</a> and <a href=\"image.htm?imageKey=NEURO%2F94771\" class=\"graphic graphic_waveform graphicRef94771 \">waveform 7</a>).</p><p>An IV antiseizure drug trial is typically performed by a neurologist or epileptologist with proper nursing support and monitoring of vital signs (ie, electrocardiogram [ECG], blood pressure, pulse oximetry). Although an IV benzodiazepine has traditionally been used, we now prefer sequential doses of a nonsedating IV antiseizure drug for the same purpose, such as <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a> (5 to 10 <span class=\"nowrap\">mg/kg</span> IV), <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> (20 <span class=\"nowrap\">mg/kg</span> IV), <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a> (20 <span class=\"nowrap\">mg/kg</span> IV), or <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">lacosamide</a> (200 mg IV) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/87,88\" class=\"abstract_t\">87,88</a>].</p><p>If using a benzodiazepine, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> is preferred in diagnostic cases because of its rapidly acting pharmacodynamic properties, as well as its short half-life. Sequential 1-mg doses of midazolam are slowly infused intravenously while monitoring the EEG as well as the patient's clinical state, ECG, blood pressure, respirations, and oxygen saturation, up to a maximum dose of approximately 0.2 <span class=\"nowrap\">mg/kg</span>. If IV <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> is used, we suggest 0.5-mg incremental doses (maximum 4 mg). After each dose, a new EEG and neurologic assessment is initiated, and the trial is stopped if there has been definite improvement in either of these two variables, or if there is evidence of respiratory depression or hypotension. This multiple small-step approach is stressed in order to avoid oversedation and consequently missing the window to make the diagnosis.</p><p>NCSE cannot be definitively diagnosed simply based on the resolution of an EEG pattern without clinical improvement, which is the most common result if one large bolus of benzodiazepine is given. Clinical improvement typically takes hours in critically ill patients. The test is only considered diagnostic for NCSE if there has been an improvement in the clinical state or if there has been a return of normal EEG rhythms (eg, posterior-dominant &quot;alpha&quot; rhythm) (<a href=\"image.htm?imageKey=NEURO%2F88654\" class=\"graphic graphic_table graphicRef88654 \">table 2</a>). Of note, if the EEG pattern resolves but the patient does not improve, no conclusion can be reached and this should be considered possible NCSE [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/62\" class=\"abstract_t\">62</a>].</p><p>Definitive positive results with a benzodiazepine trial, including the requirement for a substantial improvement in level of consciousness, were reported in 35 percent of 62 cases in one study [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/88\" class=\"abstract_t\">88</a>]. In another study of 64 patients with unexplained encephalopathy and uncertain EEG patterns, positive results (defined as resolution of the EEG pattern AND either unequivocal improvement in encephalopathy or the appearance of previously absent normal EEG patterns [eg, posterior dominant rhythm]) were reported in 19 percent of 53 benzodiazepine trials and 27 percent of 45 nonsedating IV antiseizure drug trials; an additional 16 percent had a delayed but possible response [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/87\" class=\"abstract_t\">87</a>].</p><p class=\"headingAnchor\" id=\"H3610441464\"><span class=\"h2\">Neuroimaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conventional structural brain imaging is imperceptive of seizure activity per se and is of no use for the diagnosis of NCSE. However, diffusion, perfusion, and metabolic magnetic resonance imaging (MRI) techniques may reveal indirect signs of prolonged, and potentially harmful, neuronal hyperactivity.</p><p>Examples of such signs include focal elevation of diffusion-weighted imaging (DWI) signal and reduced apparent diffusion coefficient (ADC) in the cortical ribbon, hippocampus, or thalamus [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/89\" class=\"abstract_t\">89</a>]; contrast enhancement in the same regions; focal or regional increased (18)F-2-fluoro-2-deoxy-D-glucose (FDG) cortical uptake on brain positron emission tomography (PET) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/73\" class=\"abstract_t\">73</a>]; cortical vein hyperoxygenation on susceptibility-weighted MRI (SWI) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/90,91\" class=\"abstract_t\">90,91</a>]; and focal cortical hyperperfusion on contrast-enhanced [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/90\" class=\"abstract_t\">90</a>] or contrast-free [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/91\" class=\"abstract_t\">91</a>] perfusion MRI. These changes usually resolve once NCSE is aborted. (See <a href=\"topic.htm?path=neuroimaging-in-the-evaluation-of-seizures-and-epilepsy\" class=\"medical medical_review\">&quot;Neuroimaging in the evaluation of seizures and epilepsy&quot;</a>.) </p><p>The diagnostic accuracy of advanced neuroimaging is unknown, and available data come from small, mostly uncontrolled series. Nonetheless, these advanced techniques can be used in selected complex cases to differentiate NCSE from similar patterns of nonictal nature or at least to decide if a pattern of uncertain significance is associated with signs of potential secondary cerebral injury.</p><p class=\"headingAnchor\" id=\"H2107983\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dominant clinical feature of NCSE is altered consciousness; therefore, the differential diagnosis of NCSE is broad and overlaps significantly with that of delirium and toxic-metabolic encephalopathy, which are discussed in detail separately. (See <a href=\"topic.htm?path=diagnosis-of-delirium-and-confusional-states\" class=\"medical medical_review\">&quot;Diagnosis of delirium and confusional states&quot;</a> and <a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-adults\" class=\"medical medical_review\">&quot;Acute toxic-metabolic encephalopathy in adults&quot;</a> and <a href=\"topic.htm?path=stupor-and-coma-in-adults\" class=\"medical medical_review\">&quot;Stupor and coma in adults&quot;</a>.)</p><p>As a general rule, electroencephalography (EEG) should be obtained to rule out NCSE in any patient with altered consciousness of unknown etiology or associated with a potentially epileptogenic process such as intracranial hemorrhage or central nervous system infection. Common alternative or associated diagnoses in patients being evaluated for NCSE include <span class=\"nowrap\">toxic/metabolic</span> encephalopathy and psychiatric disorders.</p><p class=\"headingAnchor\" id=\"H22466618\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H72692\"><span class=\"h2\">General considerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Classifying NCSE using the International League Against Epilepsy (ILAE) framework [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/1\" class=\"abstract_t\">1</a>] has utility for further management. Typical, atypical, and myoclonic absence status epilepticus (ASE) are most often aborted without aggressive anesthetics, and prognosis is usually excellent without evidence of neuronal damage or sequelae on later examination [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/92\" class=\"abstract_t\">92</a>]. A majority of the literature deals with critically ill patients and those in the aftermath of convulsive status epilepticus, with sparse data on treatment approaches for NCSE in patients who have only mild alteration in consciousness, such as those with focal NCSE with or without impairment in consciousness.</p><p>There is considerable controversy about whether to treat NCSE as aggressively as convulsive status epilepticus, and there are no randomized studies upon which to base treatment decisions [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/93\" class=\"abstract_t\">93</a>]. A majority of the literature deals with critically ill patients and those in the aftermath of convulsive status epilepticus, with sparse data on treatment approaches for NCSE in patients who have only mild alteration in consciousness, such as those with simple or complex partial status epilepticus.</p><p>In general, a concerted effort should be made to diagnose and treat NCSE as quickly as possible but with minimal sedation, so as to avoid inducing or prolonging coma and intubation. This practice places a high value on avoidance of harm associated with risks of deep sedation and prolonged intubation (eg, deep venous thrombosis, pneumonia, sepsis), since these risks are probably higher than the risk of neuronal injury from NCSE itself in most cases. Potential exceptions include patients with acute brain injury and those with NCSE in the aftermath of convulsive status epilepticus. (See <a href=\"#H710737\" class=\"local\">'How aggressively should one treat?'</a> below.)</p><p>Therapy should be administered under close clinical supervision and with continuous electroencephalogram (EEG) monitoring in most cases. As with other types of seizures and status epilepticus, identifying and treating the underlying etiology of the NCSE is a necessary component of successful management. This includes careful review of the medication list to identify potential causative drugs, such as a beta-lactam antibiotic in a critically ill patient with renal dysfunction. (See <a href=\"#H28783649\" class=\"local\">'Etiology'</a> above.)</p><p>Treatment of NCSE is not covered in status epilepticus guidelines published by the Neurocritical Care Society [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/2\" class=\"abstract_t\">2</a>]. Guidelines of the European Federation of Neurological Societies simply recommend treating NCSE like convulsive status epilepticus, but with additional attempts at noncoma-inducing treatment before moving to the use of anesthetic drugs [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/94\" class=\"abstract_t\">94</a>].</p><p class=\"headingAnchor\" id=\"H7996377\"><span class=\"h2\">Initial pharmacologic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unlike convulsive status epilepticus, which is a relatively uniform entity that is amenable to standard treatment algorithms, NCSE is more heterogeneous. Treatment must be tailored to the perceived urgency and morbidity of the underlying condition and the individual patient. Most medications used for the treatment of NCSE are not formally approved by regulatory agencies for any type of status epilepticus.</p><p>For the initial treatment of NCSE in adults, we suggest an intravenous (IV) benzodiazepine such as <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> in combination with a noncoma-inducing IV antiseizure drug such as <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a><span class=\"nowrap\">/<a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>,</span> <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>, <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a>, or <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">lacosamide</a>. Suggested doses are provided in the table (<a href=\"image.htm?imageKey=NEURO%2F94778\" class=\"graphic graphic_table graphicRef94778 \">table 3</a>). A typical initial regimen is lorazepam 0.1 <span class=\"nowrap\">mg/kg</span> (maximum dose 4 mg at a time) combined with any one of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">Fosphenytoin</a> 20 mg <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> equivalents <span class=\"nowrap\">(PE)/kg</span> (maximum rate 150 mg <span class=\"nowrap\">PE/minute)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">Valproate</a> (20 to 40 <span class=\"nowrap\">mg/kg</span> IV at a maximal rate of 5 <span class=\"nowrap\">mg/kg/minute)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">Levetiracetam</a> (40 to 60 <span class=\"nowrap\">mg/kg</span> IV bolus [maximum 4500 mg] over 15 minutes)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">Lacosamide</a> (400 mg IV bolus over 15 minutes)</p><p/><p>Support for the use of benzodiazepines and other antiseizure drugs for NCSE is primarily extrapolated from data in patients with convulsive status epilepticus. In clinical trials, the use of benzodiazepines for convulsive status epilepticus is associated with shorter seizure duration and a lower risk of cardiorespiratory complications compared with placebo [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/95\" class=\"abstract_t\">95</a>]. However, some observational data suggest that overtreatment (defined as using doses &gt;130 percent of the recommended doses) might be associated with a higher need of intubation [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/96\" class=\"abstract_t\">96</a>].</p><p><a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">Fosphenytoin</a><span class=\"nowrap\">/<a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a></span> is probably the most commonly used IV antiseizure drug for NCSE [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/34,97\" class=\"abstract_t\">34,97</a>], but several studies indicate that <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> might be a better alternative [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/97-99\" class=\"abstract_t\">97-99</a>]. In genetic generalized epilepsy, valproate is clearly preferred, as <span class=\"nowrap\">fosphenytoin/phenytoin</span> (as well as other sodium channel-blocking agents) may exert a paradoxic effect (<a href=\"image.htm?imageKey=NEURO%2F78021\" class=\"graphic graphic_table graphicRef78021 \">table 4</a>).</p><p><a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">Levetiracetam</a> is another safe alternative but might be less effective [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/100\" class=\"abstract_t\">100</a>]. <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">Lacosamide</a> is also usually well tolerated, and small accumulating data indicate that it may be as effective as other agents, including <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/101-104\" class=\"abstract_t\">101-104</a>]. In patients with preexisting epilepsy, optimization of antiseizure drugs currently utilized may be of value, especially when nonadherence to the outpatient regimen is suspected.</p><p>If NCSE persists, a repeat dose of <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> (0.1 <span class=\"nowrap\">mg/kg)</span> and a repeat dose of the nonsedating IV antiseizure drug (eg, <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a> 5 to 10 mg <span class=\"nowrap\">PE/kg</span> up to a maximum cumulative dose of 30 mg <span class=\"nowrap\">PE/kg)</span> are indicated.</p><p>An approach to further decision making in the setting of refractory NCSE is discussed below. (See <a href=\"#H22466636\" class=\"local\">'Refractory nonconvulsive status epilepticus'</a> below.)</p><p class=\"headingAnchor\" id=\"H710737\"><span class=\"h2\">How aggressively should one treat?</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Whether or not patients benefit from treatment for certain EEG findings, including intermittent, brief nonconvulsive seizures, is currently unknown [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/69,93\" class=\"abstract_t\">69,93</a>]. How aggressively to treat depends in large part upon how likely it is that the neurologic deficit is a consequence of the EEG findings; this relationship is not always clear, particularly in the critically ill.</p><p>The rationale for aggressive treatment is based on animal data suggesting that NCSE superimposed on acute brain injury is injurious to neurons [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/33,105\" class=\"abstract_t\">33,105</a>], as well as the following data in humans:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small studies in patients with traumatic brain injury support the notion that the acutely symptomatic brain may be more susceptible to injury from seizures, as measured by elevations in various markers of brain injury, including extracellular glutamate and lactate-to-pyruvate ratio [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/13,106-110\" class=\"abstract_t\">13,106-110</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonconvulsive seizures after intracerebral hemorrhage have been associated with hematoma expansion [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/13,31\" class=\"abstract_t\">13,31</a>], and nonconvulsive seizures after subarachnoid hemorrhage and traumatic brain injury may cause transient brain hypoxia, metabolic crisis, and increased intracranial pressure [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/110,111\" class=\"abstract_t\">110,111</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonconvulsive seizures have been associated with elevated neuron-specific enolase (NSE), a key enzyme for energy metabolism and a marker of acute brain injury as well as damage to the blood brain barrier, in the absence of other causes of brain injury beyond seizures [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/112,113\" class=\"abstract_t\">112,113</a>]. In addition, absolute levels of NSE correlated with the duration of status epilepticus, suggesting that early treatment of nonconvulsive seizures may be beneficial [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/113\" class=\"abstract_t\">113</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple observational studies in adults and children have found that NCSE and nonconvulsive seizures are independent predictors of poor outcome [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/21,24-26,105\" class=\"abstract_t\">21,24-26,105</a>] and later epilepsy [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/114\" class=\"abstract_t\">114</a>]. In addition, seizure duration and delay in diagnosis have been associated with higher mortality. </p><p/><p>The argument against aggressive treatment of some forms of NCSE is based primarily on observations that the prognosis of patients with nonconvulsive seizures or NCSE largely depends on many factors other than seizure control, of which etiology and age are probably most important [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/115-118\" class=\"abstract_t\">115-118</a>]. One retrospective study compared critically ill older patients with NCSE treated aggressively with IV benzodiazepines in an intensive care unit (ICU) with those treated less aggressively outside of the ICU because their advance directives mandated avoidance of aggressive care and intubation [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/116\" class=\"abstract_t\">116</a>]. The use of IV benzodiazepines was associated with prolonged hospitalization and increased mortality despite similar severity of illness.</p><p class=\"headingAnchor\" id=\"H22466636\"><span class=\"h2\">Refractory nonconvulsive status epilepticus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Refractory status epilepticus (RSE) refers to status epilepticus that continues despite administration of therapeutic doses of two or more antiseizure drugs. The failure to initiate timely aggressive treatment increases the likelihood of developing RSE.</p><p>Most experts are reluctant to advocate the use of anesthetic agents for NCSE, except in unusual circumstances. Examples of situations that may warrant aggressive therapy and iatrogenic coma include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subtle status epilepticus developing from generalized convulsive seizures, which has consistently been associated with poor outcomes [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32,64\" class=\"abstract_t\">32,64</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NCSE and nonconvulsive seizures in patients with acute brain injury, which have been associated with increased brain injury and metabolic stress and thus possibly warrant special attention [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/13,31,109-111,119,120\" class=\"abstract_t\">13,31,109-111,119,120</a>] (see <a href=\"#H710737\" class=\"local\">'How aggressively should one treat?'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cryptogenic new-onset refractory status epilepticus (NORSE) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/53\" class=\"abstract_t\">53</a>]</p><p/><p>In cases where sedation and coma are to be avoided, a typical approach to refractory NCSE includes sequential trials of noncoma-inducing IV antiseizure drugs not previously administered (<a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a><span class=\"nowrap\">/<a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a>,</span> <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>, <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">lacosamide</a>, and <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a>) (<a href=\"image.htm?imageKey=NEURO%2F94778\" class=\"graphic graphic_table graphicRef94778 \">table 3</a>). Of note, most medications in critically ill patients have altered pharmacokinetics due to organ failure <span class=\"nowrap\">and/or</span> low protein levels associated with a catabolic state. Higher doses and more frequent dosing may be required in some patients to achieve therapeutic steady state drug levels, particularly for valproate and levetiracetam.</p><p>Administration of certain oral antiseizure drugs such as <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">topiramate</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/121\" class=\"abstract_t\">121</a>], <a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/121\" class=\"abstract_t\">121</a>], <a href=\"topic.htm?path=clobazam-drug-information\" class=\"drug drug_general\">clobazam</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/122\" class=\"abstract_t\">122</a>], <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/123\" class=\"abstract_t\">123</a>], <a href=\"topic.htm?path=perampanel-drug-information\" class=\"drug drug_general\">perampanel</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/124,125\" class=\"abstract_t\">124,125</a>], allopregnanolone [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/126\" class=\"abstract_t\">126</a>], <a href=\"topic.htm?path=vigabatrin-drug-information\" class=\"drug drug_general\">vigabatrin</a>, or <a href=\"topic.htm?path=stiripentol-united-states-not-available-drug-information\" class=\"drug drug_general\">stiripentol</a> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/127\" class=\"abstract_t\">127</a>] may also be of some value as add-on therapies, although the evidence for these treatments is limited to small uncontrolled case series. Of note, <span class=\"nowrap\">oral/enteral</span> bioavailability may be limited in critically ill patients due to ileus, intestinal wall edema, and visceral hypoperfusion, and IV formulations are preferred when available.</p><p>If continuous administration of an anesthetic agent is preferred, the most common options are <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, and <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">pentobarbital</a>.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A systematic review comparing infusional <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, and <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">pentobarbital</a> in patients treated for refractory convulsive and nonconvulsive status epilepticus found that the overall outcome was poor (50 percent mortality), regardless of the agent utilized or the titration goal (ie, seizure suppression or background suppression) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/128\" class=\"abstract_t\">128</a>]. Pentobarbital treatment appeared to be more effective in preventing breakthrough seizures than other medications, even in cases of NCSE, which are known to be more refractory to treatment than generalized convulsive status [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/129\" class=\"abstract_t\">129</a>]. The incidence of hypotension was highest in patients treated with pentobarbital.</p><p/><p class=\"bulletIndent1\">Many of these findings could be due to interstudy differences in the doses used and the goals of treatment (seizure control versus background suppression), however. This was suggested by a series that demonstrated better efficacy and outcome in patients with RSE treated with <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> using a high-dose regimen (up to 3.3 <span class=\"nowrap\">mg/kg/hour)</span> compared with historic controls treated with a low-dose regimen (up to 0.53 <span class=\"nowrap\">mg/kg/hour)</span> [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/130\" class=\"abstract_t\">130</a>]. Another small study found that thiopental and midazolam had similar efficacy in RSE but adverse effects, including hypotension, were more common with thiopental [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/131\" class=\"abstract_t\">131</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> has a shorter half-life than <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">pentobarbital</a> and would seem to be safer than long-acting barbiturates, it has become clear that propofol infusion syndrome is an important complication. This serious complication is characterized by refractory metabolic acidosis, cardiac failure, rhabdomyolysis, and renal failure, and occurs most often with prolonged infusion at &gt;5 <span class=\"nowrap\">mg/kg/hour</span> for &gt;48 hours, and possibly traumatic or other acute brain injury [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/132,133\" class=\"abstract_t\">132,133</a>]. When propofol is used, creatine kinase, lipase and triglycerides levels, and pH should be monitored. (See <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects#H970645\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects&quot;, section on 'Propofol'</a>.)</p><p/><p>Other treatments that have been used for RSE include very high-dose <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a> (primarily in children), <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, thiopental, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, inhalational anesthetics, <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a>, electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, the ketogenic diet, hypothermia, and neurosurgery [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/134-138\" class=\"abstract_t\">134-138</a>]. Nonpharmacologic approaches, such as the ketogenic diet, have been used successfully in small studies [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/139,140\" class=\"abstract_t\">139,140</a>]. Immunomodulatory therapy is important to consider in cases of NORSE, as up to 40 percent of these cases are eventually found to have an autoimmune or paraneoplastic etiology [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-treatment-and-prognosis#H2329061511\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Treatment and prognosis&quot;, section on 'Immunomodulatory therapy'</a>.)</p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is an anesthetic agent but may raise blood pressure and thus might prove useful in critically ill patients or patients with significant hypotension induced by other sedative agents, although this effect is not always apparent [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/141\" class=\"abstract_t\">141</a>]. Steroids and other immunomodulators (IV <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>, plasma exchange) are often used in refractory cases, especially those attributed to an inflammatory or autoimmune etiology, but further study is needed [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/54,142\" class=\"abstract_t\">54,142</a>]. New classes of antiseizure drugs are also emerging, which have potential for the treatment of RSE [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/126,143,144\" class=\"abstract_t\">126,143,144</a>].</p><p>A suggested approach to treatment of RSE is presented elsewhere. (See <a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-treatment-and-prognosis#H2329061481\" class=\"medical medical_review\">&quot;Convulsive status epilepticus in adults: Treatment and prognosis&quot;, section on 'Refractory status epilepticus'</a>.)</p><p class=\"headingAnchor\" id=\"H22466652\"><span class=\"h2\">Tapering off continuous infusions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In all patients treated with continuous infusions, antiseizure drugs should be continued for 12 to 24 hours after seizures have stopped before a gradual taper is started. Our practice is to taper off continuous infusions over approximately 24 hours. If seizures recurred with a prior taper, it may be necessary to treat longer and taper more slowly the next time while maintaining high therapeutic levels of other drugs. Maintaining patients on <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a> may increase the chances of weaning off of <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">pentobarbital</a> without seizure recurrence [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/145\" class=\"abstract_t\">145</a>].</p><p class=\"headingAnchor\" id=\"H22466680\"><span class=\"h1\">OUTCOME AND PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are seemingly conflicting data on the morbidity and mortality associated with NCSE, but this is primarily due to the fact that NCSE includes two quite distinct groups of patients. Ambulatory patients, usually with a history of epilepsy, have a relatively good prognosis, whereas acutely ill, stuporous, or comatose patients with NCSE have a much poorer prognosis.</p><p>Risk factors for worse outcome include acute brain disease, severe mental status impairment, and longer seizure duration [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32,105,117,146\" class=\"abstract_t\">32,105,117,146</a>]. In a series of 100 patients with NCSE, 18 percent of patients died [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/117\" class=\"abstract_t\">117</a>]. Worse outcome was seen in patients with an acute medical (systemic or neurologic) cause of NCSE (27 percent mortality) as compared with those without an acute medical cause (3 percent). Patients with severe mental status impairment had a mortality rate of 39 percent.</p><p>Compared with convulsive status epilepticus, NCSE appears to be associated with a worse prognosis [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32,34\" class=\"abstract_t\">32,34</a>]. In a large randomized trial comparing four different treatment regimens for status epilepticus, 30-day outcomes were significantly worse for patients with NCSE compared with those with clinically overt status epilepticus (hospital discharge 9 versus 50 percent; mortality 65 versus 27 percent) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/34\" class=\"abstract_t\">34</a>]. NCSE in the aftermath of convulsive status epilepticus is also associated with higher mortality compared with those whose electroencephalogram (EEG) does not show ongoing seizures (51 versus 13 percent) [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32\" class=\"abstract_t\">32</a>].</p><p>Outcome in refractory status epilepticus (RSE), which is often nonconvulsive, is poor. Mortality is almost 50 percent, and only a minority of patients return to their premorbid functional baseline, primarily those with preexisting epilepsy and no acute brain process [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/128,129,146,147\" class=\"abstract_t\">128,129,146,147</a>]. Similar to status epilepticus in general, mortality in RSE is associated with older age, etiology (especially anoxic injury and subarachnoid hemorrhage), long seizure duration, and high Acute Physiology and Chronic Health Evaluation-2 (APACHE-2) scale scores [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/105,148,149\" class=\"abstract_t\">105,148,149</a>].</p><p>Despite these data, it should be noted that some patients with very prolonged RSE (requiring weeks to months of iatrogenic coma) still recover with an excellent outcome [<a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/150,151\" class=\"abstract_t\">150,151</a>].</p><p class=\"headingAnchor\" id=\"H3788750709\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-seizures-and-epilepsy-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Seizures and epilepsy in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H28783656\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonconvulsive seizures and nonconvulsive status epilepticus (NCSE) are recognized with increasing frequency, both in ambulatory patients with cognitive change, and even more so in the critically ill.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NCSE can be defined as a condition of ongoing or intermittent seizure activity without convulsions, without recovery of consciousness between attacks, and lasting more than 10 minutes. (See <a href=\"#H22466480\" class=\"local\">'Introduction and definition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The International League Against Epilepsy (ILAE) provides a framework for classification of NCSE. The classification has utility for both management and prognosis. (See <a href=\"#H22466573\" class=\"local\">'Electroclinical classification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The underlying causes of NCSE are varied and differ according to the patient population being studied (eg, ambulatory versus critically ill). Approximately one-half to two-thirds of patients will have a prior history of seizures or epilepsy. In the critically ill, common underlying diagnoses include subarachnoid hemorrhage, traumatic brain injury, stroke, and <span class=\"nowrap\">hypoxia/anoxia</span>. (See <a href=\"#H28783649\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Impairment of consciousness is ubiquitous during NCSE, but the severity can range from mild confusion to obtundation or coma. Subtle abnormal movements such as nystagmus, sustained eye deviation, or hippus are suggestive of NCSE in a patient with altered awareness but not sensitive for the diagnosis. In the aftermath of convulsive status epilepticus, the vast majority of breakthrough seizures will be subclinical, with no clinical accompaniment aside from depressed mental status. (See <a href=\"#H4594405\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A high index of suspicion is often necessary to confirm NCSE, since clinical signs and symptoms are pleomorphic and nonspecific, and confirmation of the diagnosis is largely based on a confirmatory electroencephalogram (EEG) showing frequent or continuous nonconvulsive seizures. (See <a href=\"#H22466611\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In the aftermath of convulsive status epilepticus and in the critically ill, EEG findings include a range of periodic or rhythmic discharges (PDs) that do not meet formal seizure criteria, but some of which are associated with nonconvulsive seizures elsewhere in the recording. (See <a href=\"#H784352\" class=\"local\">'Uncertain EEG patterns in critical illness'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When periodic discharges are present, a longer duration of continuous EEG monitoring (eg, 48 to 72 hours) should be considered to rule out nonconvulsive seizures. (See <a href=\"#H784360\" class=\"local\">'Duration of monitoring'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A trial of a fast-acting intravenous (IV) antiseizure drug is required in some cases when the EEG pattern is in doubt (ie, ictal versus nonictal), during which the clinician is looking for significant improvement in the EEG and either improved clinical state or return of a normal EEG rhythm. (See <a href=\"#H627169\" class=\"local\">'Acute IV antiseizure drug trial'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In challenging cases, diffusion, perfusion, and metabolic neuroimaging can sometimes provide useful corroborative information. (See <a href=\"#H3610441464\" class=\"local\">'Neuroimaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence (generalized) NCSE is most often easily aborted without aggressive anesthetic sedation, even after long delays in treatment initiation. Outcomes are also mostly excellent. (See <a href=\"#H28783851\" class=\"local\">'Typical absence status epilepticus'</a> above and <a href=\"#H28783858\" class=\"local\">'Atypical absence status epilepticus'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the critically ill coma population, there is considerable controversy about whether to treat NCSE as aggressively as convulsive status epilepticus. In all patients with NCSE, a concerted effort should be made to diagnose and treat seizures as quickly as possible but with minimal sedation, so as to avoid inducing or prolonging coma and intubation. (See <a href=\"#H72692\" class=\"local\">'General considerations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients presenting with NCSE, we suggest treatment with an IV benzodiazepine under closely monitored conditions with continuous EEG, combined with an IV noncoma-inducing antiseizure drug (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H7996377\" class=\"local\">'Initial pharmacologic therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A typical initial regimen is <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> 0.1 <span class=\"nowrap\">mg/kg</span> (maximum dose 4 mg at a time) combined with any one of the following: <a href=\"topic.htm?path=fosphenytoin-drug-information\" class=\"drug drug_general\">fosphenytoin</a> 20 mg <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a> equivalents <span class=\"nowrap\">(PE)/kg</span> (maximum rate 150 mg <span class=\"nowrap\">PE/minute),</span> <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> (40 <span class=\"nowrap\">mg/kg</span> IV at a maximal rate of 5 <span class=\"nowrap\">mg/kg/minute),</span> <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">levetiracetam</a> (2500 mg IV bolus over 15 minutes), or <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">lacosamide</a> (400 mg IV bolus over 15 minutes) (<a href=\"image.htm?imageKey=NEURO%2F94778\" class=\"graphic graphic_table graphicRef94778 \">table 3</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of refractory NCSE must be individualized. We favor ongoing aggressive treatment in patients with NCSE in the aftermath of generalized status epilepticus, in those with acute brain injury, and in those with cryptogenic new-onset refractory status epilepticus (NORSE). This typically requires continuous infusions of <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, or <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">pentobarbital</a>. (See <a href=\"#H22466636\" class=\"local\">'Refractory nonconvulsive status epilepticus'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are seemingly conflicting data on the morbidity and mortality associated with NCSE, but this is primarily due to the fact that NCSE includes two quite distinct groups of patients. Ambulatory patients, usually with a history of epilepsy, have a relatively good prognosis, whereas acutely ill, stuporous, or comatose patients with NCSE have a much poorer prognosis. (See <a href=\"#H22466680\" class=\"local\">'Outcome and prognosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Refractory status epilepticus (RSE) is associated with a mortality rate of up to 50 percent. Poor outcomes are driven primarily by the underlying acute process associated with NCSE rather than the seizures themselves, although prolonged nonconvulsive seizure activity may cause secondary neuronal injury, especially in those with acute brain injury. (See <a href=\"#H22466680\" class=\"local\">'Outcome and prognosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/1\" class=\"nounderline abstract_t\">Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56:1515.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/2\" class=\"nounderline abstract_t\">Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17:3.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/3\" class=\"nounderline abstract_t\">Shorvon S. What is nonconvulsive status epilepticus, and what are its subtypes? Epilepsia 2007; 48 Suppl 8:35.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/4\" class=\"nounderline abstract_t\">Panayiotopoulos CP, Koutroumanidis M, Giannakodimos S, Agathonikou A. Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status. J Neurol Neurosurg Psychiatry 1997; 63:622.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/5\" class=\"nounderline abstract_t\">Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006; 129:1281.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/6\" class=\"nounderline abstract_t\">Thomas P, Beaumanoir A, Genton P, et al. 'De novo' absence status of late onset: report of 11 cases. Neurology 1992; 42:104.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/7\" class=\"nounderline abstract_t\">Seshia SS, McLachlan RS. Aura continua. Epilepsia 2005; 46:454.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/8\" class=\"nounderline abstract_t\">Bien CG, Elger CE. Epilepsia partialis continua: semiology and differential diagnoses. Epileptic Disord 2008; 10:3.</a></li><li class=\"breakAll\">Williamson PD, Engel JJ. Complex Partial Seizures. In: Epilepsy: a comprehensive textbook, Engel JJ, Pedley TA (Eds), Lippincott-Raven, Philadelphia 1997. p.557.</li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/10\" class=\"nounderline abstract_t\">Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003; 74:189.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/11\" class=\"nounderline abstract_t\">Claassen J, Mayer SA, Kowalski RG, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004; 62:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/12\" class=\"nounderline abstract_t\">Jette N, Claassen J, Emerson RG, Hirsch LJ. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol 2006; 63:1750.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/13\" class=\"nounderline abstract_t\">Vespa PM, O'Phelan K, Shah M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology 2003; 60:1441.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/14\" class=\"nounderline abstract_t\">Pandian JD, Cascino GD, So EL, et al. Digital video-electroencephalographic monitoring in the neurological-neurosurgical intensive care unit: clinical features and outcome. Arch Neurol 2004; 61:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/15\" class=\"nounderline abstract_t\">Jordan KG. Continuous EEG and evoked potential monitoring in the neuroscience intensive care unit. J Clin Neurophysiol 1993; 10:445.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/16\" class=\"nounderline abstract_t\">Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000; 54:340.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/17\" class=\"nounderline abstract_t\">Shahwan A, Bailey C, Shekerdemian L, Harvey AS. The prevalence of seizures in comatose children in the pediatric intensive care unit: a prospective video-EEG study. Epilepsia 2010; 51:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/18\" class=\"nounderline abstract_t\">Saengpattrachai M, Sharma R, Hunjan A, et al. Nonconvulsive seizures in the pediatric intensive care unit: etiology, EEG, and brain imaging findings. Epilepsia 2006; 47:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/19\" class=\"nounderline abstract_t\">McCoy B, Hahn CD. Continuous EEG monitoring in the neonatal intensive care unit. J Clin Neurophysiol 2013; 30:106.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/20\" class=\"nounderline abstract_t\">Carrera E, Claassen J, Oddo M, et al. Continuous electroencephalographic monitoring in critically ill patients with central nervous system infections. Arch Neurol 2008; 65:1612.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/21\" class=\"nounderline abstract_t\">Oddo M, Carrera E, Claassen J, et al. Continuous electroencephalography in the medical intensive care unit. Crit Care Med 2009; 37:2051.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/22\" class=\"nounderline abstract_t\">Abend NS, Gutierrez-Colina AM, Topjian AA, et al. Nonconvulsive seizures are common in critically ill children. Neurology 2011; 76:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/23\" class=\"nounderline abstract_t\">Kamel H, Betjemann JP, Navi BB, et al. Diagnostic yield of electroencephalography in the medical and surgical intensive care unit. Neurocrit Care 2013; 19:336.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/24\" class=\"nounderline abstract_t\">Topjian AA, Gutierrez-Colina AM, Sanchez SM, et al. Electrographic status epilepticus is associated with mortality and worse short-term outcome in critically ill children. Crit Care Med 2013; 41:215.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/25\" class=\"nounderline abstract_t\">Abend NS, Arndt DH, Carpenter JL, et al. Electrographic seizures in pediatric ICU patients: cohort study of risk factors and mortality. Neurology 2013; 81:383.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/26\" class=\"nounderline abstract_t\">Kurtz P, Gaspard N, Wahl AS, et al. Continuous electroencephalography in a surgical intensive care unit. Intensive Care Med 2014; 40:228.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/27\" class=\"nounderline abstract_t\">Payne ET, Zhao XY, Frndova H, et al. Seizure burden is independently associated with short term outcome in critically ill children. Brain 2014; 137:1429.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/28\" class=\"nounderline abstract_t\">Laccheo I, Sonmezturk H, Bhatt AB, et al. Non-convulsive status epilepticus and non-convulsive seizures in neurological ICU patients. Neurocrit Care 2015; 22:202.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/29\" class=\"nounderline abstract_t\">Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999; 91:750.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/30\" class=\"nounderline abstract_t\">Privitera M, Hoffman M, Moore JL, Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res 1994; 18:155.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/31\" class=\"nounderline abstract_t\">Claassen J, Jett&eacute; N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology 2007; 69:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/32\" class=\"nounderline abstract_t\">DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39:833.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/33\" class=\"nounderline abstract_t\">Jaitly R, Sgro JA, Towne AR, et al. Prognostic value of EEG monitoring after status epilepticus: a prospective adult study. J Clin Neurophysiol 1997; 14:326.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/34\" class=\"nounderline abstract_t\">Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792.</a></li><li class=\"breakAll\">Claassen J, Hirsch LJ. Refractory status epilepticus. In: Atlas of Video-EEG Monitoring, Sirven JI, Stern JM (Eds), The McGraw-Hill Companies, Inc., 2011.</li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/36\" class=\"nounderline abstract_t\">Yeo LL, Paliwal PR, Tambyah PA, et al. Complex partial status epilepticus associated with adult H1N1 infection. J Clin Neurosci 2012; 19:1728.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/37\" class=\"nounderline abstract_t\">Bayreuther C, Bourg V, Dellamonica J, et al. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord 2009; 11:261.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/38\" class=\"nounderline abstract_t\">Tsai MH, Lee LH, Chen SD, et al. Complex partial status epilepticus as a manifestation of Hashimoto's encephalopathy. Seizure 2007; 16:713.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/39\" class=\"nounderline abstract_t\">Tsuji M, Tanaka H, Yamakawa M, et al. A case of systemic lupus erythematosus with complex partial status epilepticus. Epileptic Disord 2005; 7:249.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/40\" class=\"nounderline abstract_t\">Marano E, Briganti F, Tortora F, et al. Neurosyphilis with complex partial status epilepticus and mesiotemporal MRI abnormalities mimicking herpes simplex encephalitis. J Neurol Neurosurg Psychiatry 2004; 75:833.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/41\" class=\"nounderline abstract_t\">Jacobs DA, Fung KM, Cook NM, et al. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci 2003; 213:77.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/42\" class=\"nounderline abstract_t\">Inoue Y, Fujiwara T, Matsuda K, et al. Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic syndrome. Brain 1997; 120 ( Pt 6):939.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/43\" class=\"nounderline abstract_t\">Fugate JE, Kalimullah EA, Hocker SE, et al. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care 2013; 17:R264.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/44\" class=\"nounderline abstract_t\">Ekici A, Yakut A, Kural N, et al. Nonconvulsive status epilepticus due to drug induced neurotoxicity in chronically ill children. Brain Dev 2012; 34:824.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/45\" class=\"nounderline abstract_t\">Anzellotti F, Ricciardi L, Monaco D, et al. Cefixime-induced nonconvulsive status epilepticus. Neurol Sci 2012; 33:325.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/46\" class=\"nounderline abstract_t\">Thabet F, Al Maghrabi M, Al Barraq A, Tabarki B. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care 2009; 10:347.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/47\" class=\"nounderline abstract_t\">Naeije G, Lorent S, Vincent JL, Legros B. Continuous epileptiform discharges in patients treated with cefepime or meropenem. Arch Neurol 2011; 68:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/48\" class=\"nounderline abstract_t\">Mazzei D, Accardo J, Ferrari A, Primavera A. Levofloxacin neurotoxicity and non-convulsive status epilepticus (NCSE): a case report. Clin Neurol Neurosurg 2012; 114:1371.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/49\" class=\"nounderline abstract_t\">Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci 2014; 45:222.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/50\" class=\"nounderline abstract_t\">Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25:484.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/51\" class=\"nounderline abstract_t\">Steeghs N, de Jongh FE, Sillevis Smitt PA, van den Bent MJ. Cisplatin-induced encephalopathy and seizures. Anticancer Drugs 2003; 14:443.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/52\" class=\"nounderline abstract_t\">Kozak OS, Wijdicks EF, Manno EM, et al. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007; 69:894.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/53\" class=\"nounderline abstract_t\">Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015; 85:1604.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/54\" class=\"nounderline abstract_t\">Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy. Epilepsy Behav 2015; 47:17.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/55\" class=\"nounderline abstract_t\">Spatola M, Novy J, Du Pasquier R, et al. Status epilepticus of inflammatory etiology: a cohort study. Neurology 2015; 85:464.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/56\" class=\"nounderline abstract_t\">Foreman B, Hirsch LJ. Epilepsy emergencies: diagnosis and management. Neurol Clin 2012; 30:11.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/57\" class=\"nounderline abstract_t\">Kennedy JD, Gerard EE. Continuous EEG monitoring in the intensive care unit. Curr Neurol Neurosci Rep 2012; 12:419.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/58\" class=\"nounderline abstract_t\">Abend NS, Dlugos DJ. Nonconvulsive status epilepticus in a pediatric intensive care unit. Pediatr Neurol 2007; 37:165.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/59\" class=\"nounderline abstract_t\">Sutter R, Kaplan PW. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia 2012; 53 Suppl 3:1.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/60\" class=\"nounderline abstract_t\">Kaplan PW. The clinical features, diagnosis, and prognosis of nonconvulsive status epilepticus. Neurologist 2005; 11:348.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/61\" class=\"nounderline abstract_t\">Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006; 47:1504.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/62\" class=\"nounderline abstract_t\">Beniczky S, Hirsch LJ, Kaplan PW, et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013; 54 Suppl 6:28.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/63\" class=\"nounderline abstract_t\">Walker M, Cross H, Smith S, et al. Nonconvulsive status epilepticus: Epilepsy Research Foundation workshop reports. Epileptic Disord 2005; 7:253.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/64\" class=\"nounderline abstract_t\">Jirsch J, Hirsch LJ. Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population. Clin Neurophysiol 2007; 118:1660.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/65\" class=\"nounderline abstract_t\">Leitinger M, Beniczky S, Rohracher A, et al. Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus--approach to clinical application. Epilepsy Behav 2015; 49:158.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/66\" class=\"nounderline abstract_t\">Leitinger M, Trinka E, Gardella E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 2016; 15:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/67\" class=\"nounderline abstract_t\">Hirsch LJ, LaRoche SM, Gaspard N, et al. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version. J Clin Neurophysiol 2013; 30:1.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/68\" class=\"nounderline abstract_t\">Husain AM, Mebust KA, Radtke RA. Generalized periodic epileptiform discharges: etiologies, relationship to status epilepticus, and prognosis. J Clin Neurophysiol 1999; 16:51.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/69\" class=\"nounderline abstract_t\">Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005; 22:79.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/70\" class=\"nounderline abstract_t\">Foreman B, Claassen J, Abou Khaled K, et al. Generalized periodic discharges in the critically ill: a case-control study of 200 patients. Neurology 2012; 79:1951.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/71\" class=\"nounderline abstract_t\">Rodriguez Ruiz A, Vlachy J, Lee JW, et al. Association of Periodic and Rhythmic Electroencephalographic Patterns With Seizures in Critically Ill Patients. JAMA Neurol 2017; 74:181.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/72\" class=\"nounderline abstract_t\">Reiher J, Rivest J, Grand'Maison F, Leduc CP. Periodic lateralized epileptiform discharges with transitional rhythmic discharges: association with seizures. Electroencephalogr Clin Neurophysiol 1991; 78:12.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/73\" class=\"nounderline abstract_t\">Struck AF, Westover MB, Hall LT, et al. Metabolic Correlates of the Ictal-Interictal Continuum: FDG-PET During Continuous EEG. Neurocrit Care 2016; 24:324.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/74\" class=\"nounderline abstract_t\">Rodr&iacute;guez V, Rodden MF, LaRoche SM. Ictal-interictal continuum: A proposed treatment algorithm. Clin Neurophysiol 2016; 127:2056.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/75\" class=\"nounderline abstract_t\">Sivaraju A, Gilmore EJ. Understanding and Managing the Ictal-Interictal Continuum in Neurocritical Care. Curr Treat Options Neurol 2016; 18:8.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/76\" class=\"nounderline abstract_t\">Pohlmann-Eden B, Hoch DB, Cochius JI, Chiappa KH. Periodic lateralized epileptiform discharges--a critical review. J Clin Neurophysiol 1996; 13:519.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/77\" class=\"nounderline abstract_t\">Sen-Gupta I, Bernstein RA, Macken MP, et al. Ictal sensory periodic lateralized epileptiform discharges. Epilepsy Behav 2011; 22:796.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/78\" class=\"nounderline abstract_t\">Hirsch LJ, Claassen J, Mayer SA, Emerson RG. Stimulus-induced rhythmic, periodic, or ictal discharges (SIRPIDs): a common EEG phenomenon in the critically ill. Epilepsia 2004; 45:109.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/79\" class=\"nounderline abstract_t\">Braksick SA, Burkholder DB, Tsetsou S, et al. Associated Factors and Prognostic Implications of Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges. JAMA Neurol 2016; 73:585.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/80\" class=\"nounderline abstract_t\">Struck AF, Osman G, Rampal N, et al. Time-dependent risk of seizures in critically ill patients on continuous electroencephalogram. Ann Neurol 2017; 82:177.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/81\" class=\"nounderline abstract_t\">Shafi MM, Westover MB, Cole AJ, et al. Absence of early epileptiform abnormalities predicts lack of seizures on continuous EEG. Neurology 2012; 79:1796.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/82\" class=\"nounderline abstract_t\">Westover MB, Shafi MM, Bianchi MT, et al. The probability of seizures during EEG monitoring in critically ill adults. Clin Neurophysiol 2015; 126:463.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/83\" class=\"nounderline abstract_t\">Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: indications. J Clin Neurophysiol 2015; 32:87.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/84\" class=\"nounderline abstract_t\">Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically ill adults and children, part II: personnel, technical specifications, and clinical practice. J Clin Neurophysiol 2015; 32:96.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/85\" class=\"nounderline abstract_t\">Young GB, Sharpe MD, Savard M, et al. Seizure detection with a commercially available bedside EEG monitor and the subhairline montage. Neurocrit Care 2009; 11:411.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/86\" class=\"nounderline abstract_t\">Hern&aacute;ndez-Hern&aacute;ndez MA, Fern&aacute;ndez-Torre JL. Color density spectral array of bilateral bispectral index system: Electroencephalographic correlate in comatose patients with nonconvulsive status epilepticus. Seizure 2016; 34:18.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/87\" class=\"nounderline abstract_t\">O'Rourke D, Chen PM, Gaspard N, et al. Response Rates to Anticonvulsant Trials in Patients with Triphasic-Wave EEG Patterns of Uncertain Significance. Neurocrit Care 2016; 24:233.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/88\" class=\"nounderline abstract_t\">Hopp JL, Sanchez A, Krumholz A, et al. Nonconvulsive status epilepticus: value of a benzodiazepine trial for predicting outcomes. Neurologist 2011; 17:325.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/89\" class=\"nounderline abstract_t\">Szabo K, Poepel A, Pohlmann-Eden B, et al. Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus. Brain 2005; 128:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/90\" class=\"nounderline abstract_t\">Verma RK, Abela E, Schindler K, et al. Focal and Generalized Patterns of Cerebral Cortical Veins Due to Non-Convulsive Status Epilepticus or Prolonged Seizure Episode after Convulsive Status Epilepticus - A MRI Study Using Susceptibility Weighted Imaging. PLoS One 2016; 11:e0160495.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/91\" class=\"nounderline abstract_t\">Eisele P, Gass A, Alonso A, et al. Susceptibility-weighted MRI signs of compensatory mechanism in nonconvulsive status epilepticus. Neurology 2016; 87:116.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/92\" class=\"nounderline abstract_t\">Shirasaka Y. Lack of neuronal damage in atypical absence status epilepticus. Epilepsia 2002; 43:1498.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/93\" class=\"nounderline abstract_t\">Jordan KG, Hirsch LJ. In nonconvulsive status epilepticus (NCSE), treat to burst-suppression: pro and con. Epilepsia 2006; 47 Suppl 1:41.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/94\" class=\"nounderline abstract_t\">Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010; 17:348.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/95\" class=\"nounderline abstract_t\">Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/96\" class=\"nounderline abstract_t\">Spatola M, Alvarez V, Rossetti AO. Benzodiazepine overtreatment in status epilepticus is related to higher need of intubation and longer hospitalization. Epilepsia 2013; 54:e99.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/97\" class=\"nounderline abstract_t\">Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014; 23:167.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/98\" class=\"nounderline abstract_t\">Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67:340.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/99\" class=\"nounderline abstract_t\">Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16:527.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/100\" class=\"nounderline abstract_t\">Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011; 52:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/101\" class=\"nounderline abstract_t\">H&ouml;fler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013; 54:393.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/102\" class=\"nounderline abstract_t\">Misra UK, Dubey D, Kalita J. A randomized controlled trial of lacosamide versus sodium valproate in status epilepticus. Epilepsia 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/103\" class=\"nounderline abstract_t\">Strzelczyk A, Z&ouml;llner JP, Willems LM, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/104\" class=\"nounderline abstract_t\">Newey CR, Le NM, Ahrens C, et al. The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill. Neurocrit Care 2017; 26:273.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/105\" class=\"nounderline abstract_t\">Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996; 47:83.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/106\" class=\"nounderline abstract_t\">Bergsneider M, Hovda DA, Shalmon E, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurg 1997; 86:241.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/107\" class=\"nounderline abstract_t\">Bullock R, Zauner A, Myseros JS, et al. Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events. Ann N Y Acad Sci 1995; 765:290.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/108\" class=\"nounderline abstract_t\">Vespa P, Prins M, Ronne-Engstrom E, et al. Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. J Neurosurg 1998; 89:971.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/109\" class=\"nounderline abstract_t\">Vespa PM, Miller C, McArthur D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 2007; 35:2830.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/110\" class=\"nounderline abstract_t\">Vespa P, Tubi M, Claassen J, et al. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol 2016; 79:579.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/111\" class=\"nounderline abstract_t\">Claassen J, Perotte A, Albers D, et al. Nonconvulsive seizures after subarachnoid hemorrhage: Multimodal detection and outcomes. Ann Neurol 2013; 74:53.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/112\" class=\"nounderline abstract_t\">Correale J, Rabinowicz AL, Heck CN, et al. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology 1998; 50:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/113\" class=\"nounderline abstract_t\">DeGiorgio CM, Heck CN, Rabinowicz AL, et al. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 1999; 52:746.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/114\" class=\"nounderline abstract_t\">Wagenman KL, Blake TP, Sanchez SM, et al. Electrographic status epilepticus and long-term outcome in critically ill children. Neurology 2014; 82:396.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/115\" class=\"nounderline abstract_t\">Drislane FW, Schomer DL. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res 1994; 19:111.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/116\" class=\"nounderline abstract_t\">Litt B, Wityk RJ, Hertz SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998; 39:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/117\" class=\"nounderline abstract_t\">Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003; 61:1066.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/118\" class=\"nounderline abstract_t\">Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62:1698.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/119\" class=\"nounderline abstract_t\">Vespa PM, McArthur DL, Xu Y, et al. Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy. Neurology 2010; 75:792.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/120\" class=\"nounderline abstract_t\">Vespa P, Martin NA, Nenov V, et al. Delayed increase in extracellular glycerol with post-traumatic electrographic epileptic activity: support for the theory that seizures induce secondary injury. Acta Neurochir Suppl 2002; 81:355.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/121\" class=\"nounderline abstract_t\">Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia 2010; 51:2207.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/122\" class=\"nounderline abstract_t\">Sivakumar S, Ibrahim M, Parker D Jr, et al. Clobazam: An effective add-on therapy in refractory status epilepticus. Epilepsia 2015; 56:e83.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/123\" class=\"nounderline abstract_t\">Kellinghaus C, Berning S, St&ouml;gbauer F. Use of oxcarbazepine for treatment of refractory status epilepticus. Seizure 2014; 23:151.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/124\" class=\"nounderline abstract_t\">Redecker J, Wittstock M, Benecke R, R&ouml;sche J. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 2015; 45:176.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/125\" class=\"nounderline abstract_t\">Rohracher A, H&ouml;fler J, Kalss G, et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 2015; 49:354.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/126\" class=\"nounderline abstract_t\">Broomall E, Natale JE, Grimason M, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76:911.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/127\" class=\"nounderline abstract_t\">Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand 2015; 132:435.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/128\" class=\"nounderline abstract_t\">Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43:146.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/129\" class=\"nounderline abstract_t\">Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/130\" class=\"nounderline abstract_t\">Fernandez A, Lantigua H, Lesch C, et al. High-dose midazolam infusion for refractory status epilepticus. Neurology 2014; 82:359.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/131\" class=\"nounderline abstract_t\">Bellante F, Legros B, Depondt C, et al. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol 2016; 263:799.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/132\" class=\"nounderline abstract_t\">Cremer OL, Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357:117.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/133\" class=\"nounderline abstract_t\">Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/134\" class=\"nounderline abstract_t\">Hirsch LJ, Gaspard N. Status epilepticus. Continuum (Minneap Minn) 2013; 19:767.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/135\" class=\"nounderline abstract_t\">Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134:2802.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/136\" class=\"nounderline abstract_t\">Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012; 135:2314.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/137\" class=\"nounderline abstract_t\">Zeiler FA, Zeiler KJ, Teitelbaum J, et al. Modern inhalational anesthetics for refractory status epilepticus. Can J Neurol Sci 2015; 42:106.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/138\" class=\"nounderline abstract_t\">Zeiler FA, Zeiler KJ, Teitelbaum J, et al. VNS for refractory status epilepticus. Epilepsy Res 2015; 112:100.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/139\" class=\"nounderline abstract_t\">Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014; 82:665.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/140\" class=\"nounderline abstract_t\">Cervenka MC, Hocker S, Koenig M, et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology 2017; 88:938.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/141\" class=\"nounderline abstract_t\">Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54:1498.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/142\" class=\"nounderline abstract_t\">Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013; 22:217.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/143\" class=\"nounderline abstract_t\">Reddy K, Reife R, Cole AJ. SGE-102: a novel therapy for refractory status epilepticus. Epilepsia 2013; 54 Suppl 6:81.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/144\" class=\"nounderline abstract_t\">Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2013; 22:70.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/145\" class=\"nounderline abstract_t\">Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia 1996; 37:863.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/146\" class=\"nounderline abstract_t\">Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001; 57:1036.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/147\" class=\"nounderline abstract_t\">Hocker SE, Britton JW, Mandrekar JN, et al. Predictors of outcome in refractory status epilepticus. JAMA Neurol 2013; 70:72.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/148\" class=\"nounderline abstract_t\">Claassen J, Lokin JK, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58:139.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/149\" class=\"nounderline abstract_t\">Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35:27.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/150\" class=\"nounderline abstract_t\">Kilbride RD, Reynolds AS, Szaflarski JP, Hirsch LJ. Clinical outcomes following prolonged refractory status epilepticus (PRSE). Neurocrit Care 2013; 18:374.</a></li><li><a href=\"https://www.uptodate.com/contents/nonconvulsive-status-epilepticus/abstract/151\" class=\"nounderline abstract_t\">Lai A, Outin HD, Jabot J, et al. Functional outcome of prolonged refractory status epilepticus. Crit Care 2015; 19:199.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 14103 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28783656\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H22466480\" id=\"outline-link-H22466480\">INTRODUCTION AND DEFINITION</a></li><li><a href=\"#H22466573\" id=\"outline-link-H22466573\">ELECTROCLINICAL CLASSIFICATION</a><ul><li><a href=\"#H28783851\" id=\"outline-link-H28783851\">Typical absence status epilepticus</a></li><li><a href=\"#H28783858\" id=\"outline-link-H28783858\">Atypical absence status epilepticus</a></li><li><a href=\"#H1042785500\" id=\"outline-link-H1042785500\">Myoclonic absence status epilepticus</a></li><li><a href=\"#H15026272\" id=\"outline-link-H15026272\">Focal status epilepticus without impairment of consciousness</a></li><li><a href=\"#H28783865\" id=\"outline-link-H28783865\">Focal status epilepticus with impairment of consciousness</a></li><li><a href=\"#H542486148\" id=\"outline-link-H542486148\">Nonconvulsive status epilepticus in coma</a></li><li><a href=\"#H936096898\" id=\"outline-link-H936096898\">Aftermath of convulsive status epilepticus</a></li></ul></li><li><a href=\"#H28783642\" id=\"outline-link-H28783642\">BOUNDARY CONDITIONS</a><ul><li><a href=\"#H4073668\" id=\"outline-link-H4073668\">Neonatal and infantile epileptic encephalopathy</a></li><li><a href=\"#H784277\" id=\"outline-link-H784277\">Electrical status epilepticus of sleep</a></li><li><a href=\"#H795799703\" id=\"outline-link-H795799703\">Coma or acute confusional states with epileptiform EEG patterns</a></li></ul></li><li><a href=\"#H28783649\" id=\"outline-link-H28783649\">ETIOLOGY</a></li><li><a href=\"#H4594405\" id=\"outline-link-H4594405\">CLINICAL FEATURES</a></li><li><a href=\"#H22466611\" id=\"outline-link-H22466611\">DIAGNOSIS</a><ul><li><a href=\"#H76178\" id=\"outline-link-H76178\">Patient selection for EEG</a></li><li><a href=\"#H2970645\" id=\"outline-link-H2970645\">Electroencephalography</a><ul><li><a href=\"#H664295002\" id=\"outline-link-H664295002\">- EEG patterns of definite NCSE</a></li><li><a href=\"#H784352\" id=\"outline-link-H784352\">- Uncertain EEG patterns in critical illness</a></li><li><a href=\"#H784360\" id=\"outline-link-H784360\">- Duration of monitoring</a></li><li><a href=\"#H837656464\" id=\"outline-link-H837656464\">- EEG electrode array for monitoring</a></li></ul></li><li><a href=\"#H627169\" id=\"outline-link-H627169\">Acute IV antiseizure drug trial</a></li><li><a href=\"#H3610441464\" id=\"outline-link-H3610441464\">Neuroimaging</a></li></ul></li><li><a href=\"#H2107983\" id=\"outline-link-H2107983\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H22466618\" id=\"outline-link-H22466618\">TREATMENT</a><ul><li><a href=\"#H72692\" id=\"outline-link-H72692\">General considerations</a></li><li><a href=\"#H7996377\" id=\"outline-link-H7996377\">Initial pharmacologic therapy</a></li><li><a href=\"#H710737\" id=\"outline-link-H710737\">How aggressively should one treat?</a></li><li><a href=\"#H22466636\" id=\"outline-link-H22466636\">Refractory nonconvulsive status epilepticus</a></li><li><a href=\"#H22466652\" id=\"outline-link-H22466652\">Tapering off continuous infusions</a></li></ul></li><li><a href=\"#H22466680\" id=\"outline-link-H22466680\">OUTCOME AND PROGNOSIS</a></li><li><a href=\"#H3788750709\" id=\"outline-link-H3788750709\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H28783656\" id=\"outline-link-H28783656\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/14103|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/88652\" class=\"graphic graphic_table\">- Semiological spectrum of nonconvulsive seizures</a></li><li><a href=\"image.htm?imageKey=NEURO/88654\" class=\"graphic graphic_table\">- IV antiseizure drug trial for NCSE</a></li><li><a href=\"image.htm?imageKey=NEURO/94778\" class=\"graphic graphic_table\">- Treatment of nonconvulsive status epilepticus</a></li><li><a href=\"image.htm?imageKey=NEURO/78021\" class=\"graphic graphic_table\">- Broad- versus narrow-spectrum antiseizure drugs</a></li></ul></li><li><div id=\"NEURO/14103|Waveform\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"WAVEFORMS\">WAVEFORMS</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/88644\" class=\"graphic graphic_waveform\">- Typical absence status epilepticus</a></li><li><a href=\"image.htm?imageKey=NEPH/94773\" class=\"graphic graphic_waveform\">- Generalized periodic discharges</a></li><li><a href=\"image.htm?imageKey=NEURO/94774\" class=\"graphic graphic_waveform\">- Lateralized periodic discharges</a></li><li><a href=\"image.htm?imageKey=NEURO/94775\" class=\"graphic graphic_waveform\">- Bilateral independent periodic discharges</a></li><li><a href=\"image.htm?imageKey=NEURO/94776\" class=\"graphic graphic_waveform\">- Lateralized periodic discharges with fast rhythmic activity</a></li><li><a href=\"image.htm?imageKey=NEURO/94777\" class=\"graphic graphic_waveform\">- Stimulus-induced rhythmic delta activity</a></li><li><a href=\"image.htm?imageKey=NEURO/94771\" class=\"graphic graphic_waveform\">- Acute IV antiepileptic drug trial in suspected NCSE</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-toxic-metabolic-encephalopathy-in-adults\" class=\"medical medical_review\">Acute toxic-metabolic encephalopathy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=benign-focal-epilepsies-of-childhood\" class=\"medical medical_review\">Benign focal epilepsies of childhood</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-complications-of-status-epilepticus-in-children\" class=\"medical medical_review\">Clinical features and complications of status epilepticus in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-classification-clinical-features-and-diagnosis\" class=\"medical medical_review\">Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=convulsive-status-epilepticus-in-adults-treatment-and-prognosis\" class=\"medical medical_review\">Convulsive status epilepticus in adults: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-delirium-and-confusional-states\" class=\"medical medical_review\">Diagnosis of delirium and confusional states</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dravet-syndrome-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">Dravet syndrome: Genetics, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=electroencephalography-eeg-in-the-diagnosis-of-seizures-and-epilepsy\" class=\"medical medical_review\">Electroencephalography (EEG) in the diagnosis of seizures and epilepsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epilepsy-syndromes-in-children\" class=\"medical medical_review\">Epilepsy syndromes in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=localization-related-focal-epilepsy-causes-and-clinical-features\" class=\"medical medical_review\">Localization-related (focal) epilepsy: Causes and clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-convulsive-status-epilepticus-in-children\" class=\"medical medical_review\">Management of convulsive status epilepticus in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-epilepsy-syndromes\" class=\"medical medical_review\">Neonatal epilepsy syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuroimaging-in-the-evaluation-of-seizures-and-epilepsy\" class=\"medical medical_review\">Neuroimaging in the evaluation of seizures and epilepsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy\" class=\"medical medical_review\">Overview of neurologic complications of non-platinum cancer chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-epilepsy-in-adults\" class=\"medical medical_review\">Overview of the management of epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reversible-posterior-leukoencephalopathy-syndrome\" class=\"medical medical_review\">Reversible posterior leukoencephalopathy syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-properties-dosage-regimens-and-adverse-effects\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Properties, dosage regimens, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-seizures-and-epilepsy-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Seizures and epilepsy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stupor-and-coma-in-adults\" class=\"medical medical_review\">Stupor and coma in adults</a></li></ul></div></div>","javascript":null}